Investors

NASDAQ: STEM

Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability.

Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for spinal cord injury (SCI) and age-related macular degeneration (AMD). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product. More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
Letter to Investors
January 2015  Letter to Investors from CEO Martin McGlynn
Recent News
03/24/15StemCells, Inc. Appoints Ian Massey as President and Chief Operating Officer
NEWARK, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for disorders of the central nervous system, today announced that Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer, effective March 23, 2015. In this new role, Dr. Massey has direct responsibility for all aspects of the Company's research and development, manufacturing, regulatory affairs, and quality as... 
Printer Friendly Version
03/16/15StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
Conference Call to be Hosted March 16, 2015 at 4:30 p.m. EDT (1:30 PM PDT) NEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014. "We achieved three significant clinical translation milestones in 2014: the completi... 
Printer Friendly Version
03/10/15StemCells, Inc. to Participate at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., March 10, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Management will make a presentation on the Company's programs and operations at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference. Management is scheduled to speak at 10:35 a.m. Eastern Daylight Time on Thursday, March 19, at The University Club located at 1 West 54th Street in NYC. ... 
Printer Friendly Version
03/09/15StemCells, Inc. Announces Webcast to Discuss Fourth Quarter and Full Year 2014 Financial Results
NEWARK, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014, after the market close on Monday, March 16. StemCells will host a conference call and webcast to discuss its results and an update on its business ... 
Printer Friendly Version
More >>
Upcoming Events
DateTitle
04/27/15
GTC Stem Cell Summit 2015
LocationBoston, MA
Presentations
DateTitle
11/20/14
Download Documentation StemCells, Inc. Investor and Analyst Event
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.03
Change (%) Stock is Up 0.04 (4.04%)
Volume547,847
Data as of 03/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet